Companies · AI / ML
San Francisco · CA, USA; Remote · AI / ML · founded 2016 · https://www.mdalgorithms.com
Diligence memoA one-page analyst read on MDalgorithms Inc. — recommendation, valuation, rhythm, risks.→MDalgorithms Inc.: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
MDalgorithms Inc. is one of 2067 AI / ML companies tracked from San Francisco, CA, USA; Remote, on record since 2016. By capital raised it ranks mid-pack (ahead of 62% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Democratizing Dermatology with AI
MDalgorithms is revolutionizing dermatology by delivering convenient, effective AI-powered solutions for skin and hair care. Since pioneering machine-learning models for acne treatment in 2017, we’ve advanced to develop the world’s first AI-powered scalp analysis for hair regrowth. Our proprietary AI technology, built entirely in-house, analyzes blemishes, lesions, and hair conditions with unmatched precision, utilizing the largest global dataset of acne and scalp images. Clinically validated and tested by dermatologists, our personalized treatment kits—MDacne for acne and MDhair for hair regrowth—are customized to each individual’s unique needs, combining over 100 medical and botanical ingredients for optimal results. We empower users to track their progress, adjust treatments as needed, and access real-time support from our team of dermatologists and nurses. By doing so, we make personalized dermatological care accessible to all.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 2067 companies in AI / ML. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 62% of sector peers (real $). Modeled value above 62% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
MDalgorithms Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Accord | AI / ML | — | — | — | same sector |
| Acely | AI / ML | — | — | — | same sector |
| Aedilic | AI / ML | — | — | — | same sector |
| Aemon | AI / ML | — | — | — | same sector |
| Affogato AI | AI / ML | — | — | — | same sector |
| Aftercare | AI / ML | — | — | — | same sector |
| Agentic Labs | AI / ML | — | — | — | same sector |
| Ai Aiba | AI / ML | — | — | — | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| PROVEN Group, Inc. PROVEN is using AI, data and personalization to disrupt CPG | AI / ML | Series A | $238.8M | 75% |
| mdhub AI-native operating system for behavioral health clinics. | Healthtech | — | — | 74% |
| Tissue Differentiation Intelligence, LLC | AI / ML | Series A | $216.8M | 74% |
| Datrics Generative AI Healthcare Coding Automation | Insurance | — | — | 73% |
| BioStack Platforms Real world training envs for healthcare AI models | Pharma | — | — | 73% |
| Artificial Intelligence Medical Services, Inc. | Biotechnology | Pre-Seed | $797K | 73% |
| Strand AI Multimodal foundation models to predict uncollected patient biology | Pharma | — | — | 72% |
| Triomics, Inc. AI Agents for Oncology EHRs | Pharma | Series A | $142.0M | 72% |
See where MDalgorithms Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at MDalgorithms Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.